The Science of
Human Longevity

The story begins in 1921, when Canadian scientists Frederick Banting and Charles Best extracted insulin from a dog's pancreas and used it to save the life of a 14-year-old boy dying of diabetes. Insulin is a peptide — a short chain of 51 amino acids — and its discovery proved that the body uses these small protein fragments as powerful chemical messengers. Within a year, pharmaceutical production began and millions of lives were saved. This single discovery established peptides as legitimate medicine and ignited decades of research into what else these molecules could do.

Once researchers understood insulin, they began hunting for other peptides in the body. The 1950s and 60s saw the discovery and synthesis of oxytocin (the bonding hormone), vasopressin (which regulates blood pressure and water retention), and ACTH — the brain's stress-signalling peptide, which would later become the basis for Semax. In 1963, the first synthetic peptide hormone was manufactured in a lab, opening the door to creating peptide medicines that didn't require harvesting from animals. By the 1970s, scientists had established that the body communicates at a cellular level through thousands of these small molecules, and that replicating or modifying them could have profound therapeutic effects.

While Western research focused on treating specific diseases, Soviet scientists — most notably Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology — took a different approach. They asked: what if small peptides could be used not to treat illness, but to slow aging itself? Beginning in the 1980s, Khavinson's team extracted peptide complexes from animal organs (thymus, pineal gland, brain cortex) and tested their effects on aging. They discovered that tiny tripeptides and tetrapeptides — some as small as 3 amino acids — could penetrate cell nuclei and directly influence gene expression, essentially resetting cells toward a younger biological profile. This work produced Epithalamin (the precursor to Epitalon), Thymalin (the precursor to Thymosin-based therapies), and the peptide bioregulators Selank and Semax, which were approved as prescription drugs in Russia in the 1990s.

The 1990s brought two landmark discoveries in regenerative peptide science. In Croatia, Dr. Predrag Sikiric isolated BPC-157 from human gastric juice — a peptide the stomach naturally produces to protect itself from its own acid — and found that when given in small doses, it dramatically accelerated healing of tendons, muscles, nerves, and the gut lining. Simultaneously, chemist Loren Pickart at the University of California discovered that GHK-Cu (a copper-binding tripeptide naturally found in blood) could penetrate cell nuclei and reset the activity of thousands of genes toward a younger, more regenerative pattern. Both peptides entered extensive preclinical research programmes that continued through the 2000s and 2010s.

The 2009 Nobel Prize in Physiology was awarded for the discovery that telomeres — the protective caps on chromosomes — shorten with every cell division, and that this shortening is a primary driver of biological aging. When telomeres become too short, cells stop dividing and enter a state called senescence, driving aging and disease. Scientists had already been working on this problem: Khavinson's team had identified that Epitalon (the synthetic tetrapeptide AEDG they derived from Epithalamin) activated telomerase — the enzyme that rebuilds telomere caps. Clinical studies conducted in the early 2000s confirmed that Epitalon measurably increased telomere length in human blood cells, making it the only peptide with direct human evidence of telomere extension. These studies remain among the most significant in longevity science.

A landmark 2015 paper in Cell Metabolism described a molecule scientists had never seen before: MOTS-c, a peptide encoded not in the cell's nucleus but in its mitochondria — the ancient energy-producing organelles inside every cell. This was revolutionary because it meant mitochondria had their own hormone system, communicating with the rest of the body independently of the genome. MOTS-c levels naturally decline with age and rise sharply during exercise, and restoring those levels in aged mice reversed many markers of metabolic aging. The same decade saw major advances in immune peptides: Thymosin Alpha-1 (already approved in 35+ countries for hepatitis and cancer support) was studied in thousands of patients, and its role in reversing immune aging — known as immunosenescence — became increasingly well understood.

The 2020s have been defined by a peptide revolution in metabolic medicine. GLP-1 agonists (semaglutide, tirzepatide) became the fastest-growing class of drugs in pharmaceutical history, demonstrating that peptide-based interventions could produce outcomes — 15–20% body weight loss — that no previous drug had achieved. Building on this, next-generation compounds like Retatrutide (a triple GLP-1/GIP/glucagon agonist) entered Phase 3 trials showing up to 28.7% body weight loss. Meanwhile, the entire field of longevity medicine underwent a cultural shift: peptide bioregulators, once confined to Soviet research and specialist clinics, entered mainstream longevity practice, with thousands of physicians worldwide now incorporating Epitalon, Semax, BPC-157 and related compounds into personalised anti-aging protocols. The science has never moved faster.

We are now at an inflection point in peptide science. The foundational research — spanning insulin's discovery in the 1920s through the Soviet bioregulator programmes of the 1980s, the healing peptide breakthroughs of the 1990s, the telomere science of the 2000s, and the metabolic revolution of the 2020's — has converged into a coherent picture: the body uses short peptide signals to regulate virtually every aspect of its biology, and providing those signals in a targeted, cyclic way can meaningfully improve how we age. What was once available only to elite athletes and research clinics is now accessible to anyone willing to invest in understanding the science. That is precisely what Longevix was created to do.